Rha Eun Young, Kim Yun Ho, Kim Tae-Jung, Yoo Gyeol, Rhie Jong Won, Kim Hyun-Jung, Park Il-Kyu
Seoul, Republic of Korea From the Departments of Plastic and Reconstructive Surgery and Hospital Pathology, College of Medicine, The Catholic University of Korea; and the Genewel R & D Center.
Plast Reconstr Surg. 2016 Jan;137(1):144-151. doi: 10.1097/PRS.0000000000001889.
The authors developed a novel treatment based on the topical application of a silicone gel sheet containing verapamil microparticles. The ability of these silicone gel sheets to inhibit hypertrophic scar in a rabbit ear wound model was examined.
Ten New Zealand White rabbits with a total of 80 wounds in both ears were used in this study. The rabbits were divided into five groups (control; silicone gel sheet; and silicone gel sheet plus 0.25, 2.5, and 25 mg of verapamil per gram). Histopathologic findings were quantified.
The mean scar elevation index, fibroblast counts, and capillary counts differed significantly among the five groups (p < 0.05). The median scar elevation index was significantly lower in the silicone gel sheet plus 2.5 mg of verapamil per gram group than in the silicone gel sheet group (1.2 versus 2.2). The median number of fibroblasts was significantly lower in the silicone gel sheet plus 0.25 mg of verapamil per gram group than in the silicone gel sheet group (172.5 versus 243). In the median number of capillary lumina, there was no significant difference between the silicone gel sheet group and the silicone gel sheet plus 0.25, 2.5, and 25 mg of verapamil per gram groups (28.5, 18, 20, and 18, respectively).
Topical application of a silicone gel sheet with verapamil microparticles may be a novel, effective treatment method for hypertrophic scar, but its safety and efficacy in humans must be tested in clinical trials.
作者研发了一种基于局部应用含维拉帕米微粒的硅胶片的新型治疗方法。研究了这些硅胶片在兔耳伤口模型中抑制增生性瘢痕的能力。
本研究使用了10只新西兰白兔，双耳共有80处伤口。将兔子分为五组（对照组；硅胶片组；以及每克硅胶片分别添加0.25、2.5和25毫克维拉帕米的组）。对组织病理学结果进行量化。
五组之间的平均瘢痕隆起指数、成纤维细胞计数和毛细血管计数差异有统计学意义（p < 0.05）。每克硅胶片添加2.5毫克维拉帕米组的中位瘢痕隆起指数显著低于硅胶片组（分别为1.2和2.2）。每克硅胶片添加0.25毫克维拉帕米组的成纤维细胞中位计数显著低于硅胶片组（分别为172.5和243）。在毛细血管腔的中位数量方面，硅胶片组与每克硅胶片添加0.25、2.5和25毫克维拉帕米的组之间无显著差异（分别为28.5、18、20和18）。
局部应用含维拉帕米微粒的硅胶片可能是一种治疗增生性瘢痕的新型有效方法，但其在人体中的安全性和有效性必须在临床试验中进行检验。
